Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts

Bone

Volumn 49, Issue 3, 2011, Pages 559-567

  Tat, Steeve Kwan ^a   Pelletier, Jean Pierre ^a   Mineau, François ^a   Caron, Judith ^a   Martel Pelletier, Johanne ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Osteoarthritis; Osteoblasts; Strontium ranelate; Subchondral bone

Indexed keywords

ADAM17 PROTEIN; ADAM19 PROTEIN; GELATINASE A; GELATINASE B; MT1 MMP PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEINASE; RECEPTOR ACTIVATOR OF KAPPAB LIGAND 1; RECEPTOR ACTIVATOR OF KAPPAB LIGAND 3; STRONTIUM RANELATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE REMODELING; CELL MEMBRANE; CELLULAR DISTRIBUTION; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; OSTEOARTHRITIS; OSTEOBLAST; OSTEOLYSIS; SUBCHONDRAL BONE OSTEOBLAST; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; CELLS, CULTURED; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOARTHRITIS; OSTEOBLASTS; PROTEIN ISOFORMS; RANK LIGAND; THIOPHENES;

EID: 79960615013     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.06.005     Document Type: Article

References (47)

1. Teitelbaum S.L., Tondravi M.M., Ross F.P. Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. J Leukoc Biol 1997, 61:381-388.
2. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.
3. Armstrong A.P., Tometsko M.E., Glaccum M., Sutherland C.L., Cosman D., Dougall W.C. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 2002, 277:44347-44356.
4. Darnay B.G., Haridas V., Ni J., Moore P.A., Aggarwal B.B. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem 1998, 273:20551-20555.
5. Gravallese E.M., Goldring S.R. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000, 43:2143-2151.
6. Martel-Pelletier J., Lajeunesse D., Pelletier J.P. Etiopathogenesis of osteoarthritis. Arthritis & Allied Conditions. A Textbook of Rheumatology 2005, 2199-2226. Lippincott, Williams & Wilkins, Baltimore. 15th ed. W.J. Koopman, L.W. Moreland (Eds.).
7. Bettica P., Cline G., Hart D.J., Meyer J., Spector T.D. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002, 46:3178-3184.
8. Dieppe P., Cushnaghan J., Young P., Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 1993, 52:557-563.
9. Hilal G., Martel-Pelletier J., Pelletier J.P., Duval N., Lajeunesse D. Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. Arthritis Rheum 1999, 42:2112-2122.
10. Hilal G., Martel-Pelletier J., Pelletier J.P., Ranger P., Lajeunesse D. Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: Possible role in subchondral bone sclerosis. Arthritis Rheum 1998, 41:891-899.
11. Hough A.J. Pathology of osteoarthritis. Arthritis and Allied Conditions 1997, 1945-1968. Williams and Wilkins, Baltimore. 13th ed. W.J. Koopman (Ed.).
12. Massicotte F., Lajeunesse D., Benderdour M., Pelletier J.-P., Hilal G., Duval N., et al. Can altered production of interleukin 1beta, interleukin-6, transforming growth factor-beta and prostaglandin E2 by isolated human subchondral osteoblasts identify two subgroups of osteoarthritic patients. Osteoarthritis Cartilage 2002, 10:491-500.
13. Kwan Tat S., Lajeunesse D., Pelletier J.P., Martel-Pelletier J. Targeting subchondral bone for treating osteoarthritis: what is the evidence?. Best Pract Res Clin Rheumatol 2010, 24:51-70.
14. Reginster J.Y., Deroisy R., Dougados M., Jupsin I., Colette J., Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002, 13:925-931.
15. Meunier P.J., Slosman D.O., Delmas P.D., Sebert J.L., Brandi M.L., Albanese C., et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002, 87:2060-2066.
16. Bruyere O., Delferriere D., Roux C., Wark J.D., Spector T., Devogelaer J.P., et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008, 67:335-339.
17. Alexandersen P., Karsdal M.A., Byrjalsen I., Christiansen C. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric 2011, 14:236-243.
18. Baron R., Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002, 450:11-17.
19. Bonnelye E., Chabadel A., Saltel F., Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 2008, 42:129-138.
20. Mentaverri R., Hurtel A.S., Kamel S., Robin B., Brazier M. Strontium ranelate directly stimulates osteoclast apoptosis. Osteoporos Int 2004, 15(Suppl. 1). P345MO (abstract).
21. Takahashi N., Sasaki T., Tsouderos Y., Suda T. S 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003, 18:1082-1087.
22. Altman R.D., Asch E., Bloch D.A., Bole G., Borenstein D., Brandt K.D., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986, 29:1039-1049.
23. Kwan Tat S., Pelletier J.P., Lajeunesse D., Fahmi H., Lavigne M., Martel-Pelletier J. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol 2008, 26:295-304.
24. Brennan T., Rybchyn M., Conigrave A., Mason R. Strontium ranelate effects on bone formation and bone resorption: an in vitro in human osteoblasts. Osteoporos Int 2007, 18:S166-S167.
25. Tat S.K., Pelletier J.P., Lajeunesse D., Fahmi H., Duval N., Martel-Pelletier J. Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors. Bone 2008, 43:284-291.
26. Boileau C., Amiable N., Martel-Pelletier J., Fahmi H., Duval N., Pelletier J.P. Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study. Arthritis Res Ther 2007, 9:R121.
27. Pelletier J.P., Boileau C., Brunet J., Boily M., Lajeunesse D., Reboul P., et al. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 2004, 34:527-538.
28. Carlson C.S., Loeser R.F., Jayo M.J., Weaver D.S., Adams M.R., Jerome C.P. Osteoarthritis in cynomolgus macaques: a primate model of naturally occurring disease. J Orthop Res 1994, 12:331-339.
29. Evans R.G., Collins C., Miller P., Ponsford F.M., Elson C.J. Radiological scoring of osteoarthritis progression in STR/ORT mice. Osteoarthritis Cartilage 1994, 2:103-109.
30. Carlson C.S., Loeser R.F., Purser C.B., Gardin J.F., Jerome C.P. Osteoarthritis in cynomolgus macaques. III: Effects of age, gender, and subchondral bone thickness on the severity of disease. J Bone Miner Res 1996, 11:1209-1217.
31. Watson P.J., Hall L.D., Malcolm A., Tyler J.A. Degenerative joint disease in the guinea pig. Use of magnetic resonance imaging to monitor progression of bone pathology. Arthritis Rheum 1996, 39:1327-1337.
32. Rifas L., Fausto A., Scott M.J., Avioli L.V., Welgus H.G. Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: differentiation is associated with repression of metalloproteinase biosynthesis. Endocrinology 1994, 134:213-221.
33. Itoh T., Matsuda H., Tanioka M., Kuwabara K., Itohara S., Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 2002, 169:2643-2647.
34. Ishibashi O., Niwa S., Kadoyama K., Inui T. MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. Life Sci 2006, 79:1657-1660.
35. Brennan T., Rybchyn M.S., Cornigrave A.D. Strontium ranelate effect on proliferation and OPG expression in osteoblasts. Calcif Tissue Int 2006, 78:S129. (abstract).
36. Atkins G.J., Welldon K.J., Halbout P., Findlay D.M. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 2009, 20:653-664.
37. Kadri A., Ea H.K., Bazille C., Hannouche D., Liote F., Cohen-Solal M.E. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum 2008, 58:2379-2386.
38. Brennan T.C., Rybchyn M.S., Green W., Atwa S., Conigrave A.D., Mason R.S. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 2009, 157:1291-1300.
39. Lum L., Wong B.R., Josien R., Becherer J.D., Erdjument-Bromage H., Schlondorff J., et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999, 274:13613-13618.
40. Schlondorff J., Lum L., Blobel C.P. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J Biol Chem 2001, 276:14665-14674.
41. Chesneau V., Becherer J.D., Zheng Y., Erdjument-Bromage H., Tempst P., Blobel C.P. Catalytic properties of ADAM19. J Biol Chem 2003, 278:22331-22340.
42. 2+-promoted Ras inactivator as a possible regulator of RANKL shedding. J Biol Chem 2005, 280:41700-41706.
43. Ikeda T., Kasai M., Suzuki J., Kuroyama H., Seki S., Utsuyama M., et al. Multimerization of the receptor activator of nuclear factor-kappaB ligand (RANKL) isoforms and regulation of osteoclastogenesis. J Biol Chem 2003, 278:47217-47222.
44. Ikeda T., Kasai M., Utsuyama M., Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 2001, 142:1419-1426.
45. Suzuki J., Ikeda T., Kuroyama H., Seki S., Kasai M., Utsuyama M., et al. Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem Biophys Res Commun 2004, 314:1021-1027.
46. Aoki S., Honma M., Kariya Y., Nakamichi Y., Ninomiya T., Takahashi N., et al. Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis. J Bone Miner Res 2010, 25:1907-1921.
47. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000, 275:768-775.